

Human and Zebrafish Nuclear Progesterone Receptors Are Differently Activated by Manifold Progestins

Clémentine Garoche, Selim Aït-Aïssa, Abdelhay Boulahtouf, Nicolas Creusot, Nathalie Hinfray, William Bourguet, Patrick Balaguer, François Brion

▶ To cite this version:

Clémentine Garoche, Selim Aït-Aïssa, Abdelhay Boulahtouf, Nicolas Creusot, Nathalie Hinfray, et al.. Human and Zebrafish Nuclear Progesterone Receptors Are Differently Activated by Manifold Progestins. Environmental Science and Technology, 2020, 54 (15), pp.9510-9518. 10.1021/acs.est.0c02056. hal-04707325

HAL Id: hal-04707325 https://hal.science/hal-04707325v1

Submitted on 25 Sep 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.




Human and zebrafish nuclear progesterone receptors are differently activated by 1 progestins 2 Clémentine Garoche ^a, Selim Aït-Aïssa ^{a,*}, Abdelhay Boulahtouf ^b, Nicolas Creusot ^b, 3 Nathalie Hinfray^a, William Bourget^c, Patrick Balaguer^b, François Brion^{a,*} 4 ^a Institut National de l'Environnement Industriel et des Risques (INERIS), Unité 5 6 Écotoxicologie in vitro et in vivo, UMR-I 02-SEBIO, Parc ALATA, 60550 Verneuil-en-7 Halatte, France ^b Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Université 8 Montpellier, Institut régional du Cancer de Montpellier (ICM), 34290 Montpellier, France 9 ^c Centre de Biochimie Structurale (CBS), Inserm, CNRS, Univ Montpellier, Montpellier, 10 11 France 12 13 14 * Corresponding authors: E-mail: francois.brion@ineris.fr, phone +33(0)3 44 55 65 12 15 E-mail: selim.ait-aissa@ineris.fr, phone +33(0)3 44 55 65 11 16 17 18 19

20

- 21 Keywords: synthetic progestins; 17α,20β-dihydroxy-4-pregnen-3-one; human and zebrafish
- 22 nuclear progesterone receptor; luciferase reporter cell lines.

23 Graphical abstract



Abstract

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

Environmental risk of natural and synthetic ligands of the nuclear progesterone receptor (nPR) has been pointed out, however there is still a lack of mechanistic information regarding their ability to interact with nuclear PR in aquatic species. To identify possible interspecies differences, we assessed in vitro the ability of a broad range of progestins to transactivate zebrafish (zf) and human (h) PRs, by using two established reporter cell lines, U2OS-zfPR and HELN-hPR, respectively. Reference ligands highlighted some differences between the two receptors. The reference human agonist ligands promegestone (R5020) and progesterone (P4) induced luciferase activity in both cell lines in a concentration-dependent manner whereas the natural zebrafish progestin 17α,20β-dihydroxy-4-pregnen-3-one (DHP) activated zfPR but not hPR. The potent human PR antagonist mifepristone (RU486) blocked PRinduced luciferase in both cell models but with different potencies. In addition, a large set of twenty-two synthetic progestins were screened on the two cell lines. Interestingly, all of the tested compounds activated hPR in the HELN-hPR cell line whereas the majority of them acted as zfPR antagonists in U2OS-zfPR. Such zfPR-specific response was further confirmed in zebrafish liver cells (ZFL). This study provides novel information regarding the activity of a large set of progestins on human and zebrafish PR and highlights major interspecies differences in their activity, which may result in differential effects of progestins between fish and humans.

1. Introduction

Progestagenic sex steroids, also called progestins or progestogens, play crucial roles in development and reproduction in vertebrates, including teleosts. Progesterone (P4) is an endogenous biologically active progestin in mammals and fish. However, in most teleost species including zebrafish, other endogenous active progestins such as 17α ,20 β -dihydroxy-4-pregnen-3-one (DHP) and 17α ,20 β ,21-trihydroxy-4-pregnen-3-one (20 β -S) ¹ are also synthesized, P4 being considered as an intermediate. Progestins can exert their biological activity by acting through the nuclear progesterone receptor (nPR), a ligand-activated transcription factor that belongs to the steroid hormone receptor superfamily (Grim et al., 2016). In both mammals and fish, PRs are widely distributed in different reproductive and non-reproductive tissues, suggesting the widespread physiological effects of progestagenic hormones ². Indeed, the central role of nPR in mediating progesterone-regulated reproductive functions in diverse vertebrates, in both males and females, has been demonstrated in different vertebrate models, notably by using PR knockout (PRKO) mice ³ and more recently PRKO zebrafish ^{4,5}.

During the last few years, several studies have documented the presence of progesterone and synthetic progestins in effluents of wastewater treatment plants (WWTPs) and surface waters, related to their production and consumption as pharmaceuticals in a diversity of medical applications such as contraception ^{6–10}. Laboratory studies on aquatic models revealed the effects of natural and synthetic progestins on fish reproduction at environmentally relevant concentrations (*i.e.* in the ng/L range), thereby highlighting the risks they pose on aquatic species and aquatic ecosystems ^{11,12}. Important steps forward have been recently made regarding the ability of some synthetic progestins to interfere with key endocrine molecular and cellular targets, such as human androgen receptor (AR)- and estrogen receptor (ER)-mediated signaling pathways and steroidogenesis, which could, at least partly, explain their

reproductive physiological effects *in vivo* ^{13–18}. However, it is noticeable that much less information is available regarding the ability of progesterone and synthetic progestins to interact with fish nPR ^{19,20} and subsequently alter nPR-regulated physiological processes ². Because cross-species variations in nuclear receptor (NR) sequences can significantly influence their structure, functioning and response to chemical ligands ²¹, there is a need for characterizing the ability of environmentally occurring progestins to interact with fish nPR to assess their environmental hazard to fish species.

The aim of this study was therefore i) to gain knowledge on the ability of a large set of (anti) progestagenic compounds to transactivate the zebrafish nPR and ii) to compare these results with their activity towards the human hPR (hPR, isoform B) to identify possible interspecies differences. To this end, we first developed a novel *in vitro* luciferase-reporter-gene cell line expressing the zebrafish PR, namely U2OS-zfPR. The activity of four natural or synthetic PR-ligands used as reference substances, *i.e.* P4, DHP, promegestone (R5020), mifepristone (RU486), as well as twenty-two pharmaceutical progestins representative of different chemical classes were assessed in this newly established U2OS-zfPR cell line. All the substances were also tested in an already established human cell line HELN-hPRB expressing hPRB ²² for comparative purpose.

2. Material and Methods

87

88

104

105

106

107

108

109

110

111

2.1. Chemicals and materials

Materials for cell culture are from Life Technologies (Cergy-Pontoise, France). Luciferin 89 (sodium salt) was purchased from Promega (Charbonnières, France). Chemical substances 90 used in this study are presented in Table 1. 17β-estradiol (E2), testosterone (T), 11-91 ketotestosterone (11-KT), pregnenolone (P5), progesterone (P4), dydrogesterone (DYD), 92 medroxyprogesterone (MEP), medroxyprogesterone acetate (MPA), megestrol acetate 93 (MGA), chlormadinone acetate (CMA), cyproterone acetate (CPA), promegestone (R5020), 94 nestorone (NES), nomegestrol acetate (NGA), ethisterone (ETH), ethynodiol diacetate (EDA), 95 lynestrenol (LYN), norethindrone acetate (NEA), norethindrone (NET), tibolone (TIB), 96 97 desogestrel (DSG), etonogestrel (ENG), gestodene (GES), levonorgestrel (LNG), norgestimate (NTE), norgestrel (NGL), drospirenone (DRO), mifepristone (RU486), 17α,20β-98 dihydroxy-4-pregnen-3-one (DHP), spironolactone (SPIRO) and canrenone (CAN) were 99 obtained from Sigma-Aldrich Chemical Co. (St.Louis, MO). Gestonorone (GRN) was 100 obtained from Toronto Research Chemicals (Toronto, Canada). Stock solutions of chemicals 101 were prepared in dimethyl sulfoxide (DMSO) and stored at -20°C. Fresh dilutions of test 102 chemicals in medium were prepared before each experiment. 103

2.2. Reporter gene cell lines HELN-hPR and U2OS-zfPR

To assess the ability of progestins to transactivate the human PR (hPR, isoform B) or the zebrafish PR (zfPR), two human luciferase-reporter-gene cell lines were established. The HELN-hPR cell line has already been described 22 . Briefly, HELN-hPR cells were obtained by stably transfection of HELN (HeLa ERE-luciferase-neomycin) cells 23 by a plasmid expressing hPR where the DNA binding domain was replaced by the hER α DNA binding domain (pSG5-hPR(ER α DBD)-puromycin. The U2OS-zfPR cell line was obtained by stable cotransfection of the plasmid ERE-Luciferase and an expression plasmid of zfPR with the

hER α DNA binding domain ((pSG5-hPR(ER α DBD)-puromycin, supporting Information,

Figure S1). Selection of HELN-hPRcells was made with 0.5 μg/mL puromycin and 1 mg/L

G418 and selection of USO2-zfPR cells was made with 0.5 μg/mL puromycin..

Cell lines were grown in Dulbecco's Modified Eagle's Medium (DMEM) containing phenol red, 1 g/L glucose, 5% fetal bovine serum (FBS), 100 units/mL of penicillin, and 100 μg/mL of streptomycin. Culture medium was supplemented with 0.5 μg/mL puromycin and 1 mg/mL geneticin for HELN-hPR and 0.5 μg/mL puromycin for U20S-zfPR cells. Cells were cultured in a 5% CO₂ humidified atmosphere at 37°C. Exposure was made in phenol red-free DMEM supplemented with 2% dextran-coated charcoal FBS (DCC), 100 units/mL of penicillin, and 100 μg/mL of streptomycin.

2.3. Reporter gene cell line ZFL-PR

Zebrafish liver cells ZFL cells have been stably cotransfected by the luciferase plasmid ARE₆-collagenase-Luciferase-hygromycine) and the zfPR expressing plasmid pSG5-zfPR-puromycin and grown in presence of 0.5 μ g/mL puromycin and 0.25 mg/mL hygromycin during 3 weeks. Among the different resistant clones, the one which expresses luciferase in the most inductible manner (4 fold) was selected and called ZFL-PR.

The cells were grown in LDF medium (50% Leibovitz 15 culture medium L15, 35% DMEM high glucose, and 15% Ham's-F12 medium) with 0.15 g/L sodium bicarbonate, 15 mM 4-(2-hydroxy- ethyl)-1-piperazineethanesulfonic acid (HEPES), 0.01 mg/mL insulin, 50 ng/mL epidermal growth factor (EGF), 5% fetal bovine serum (FBS), and 50 U/mL penicillin and streptomycin antibiotics and supplemented with 5% vol/vol FBS. Cells were cultured in a 5% CO₂ humidified atmosphere at 28°C. Exposure was made in LDF supplemented with 2% dextran-coated charcoal FBS (DCC), 100 units/mL of penicillin, and 100 μg/mL of streptomycin.

2.4. In vitro transcriptional activation bioassays

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

HELN-hPR and U20S-zfPR cells were seeded in 96-wells white opaque culture plates (Greiner CellStar; Dutscher, Brumath, France) at a density of 7×10^4 cells per well in 100 µL culture medium. After 24h, cells were exposed by adding serial dilutions of compounds or solvent control (DMSO; final concentration 0.1% v/v) in triplicates and incubated for 16h. For antagonist activity assessment, cells were exposed to different concentrations of the tested compounds and to a concentration of the reference compound that yield 50%-80% of the maximal response, i.e. R5020 at 10⁻⁹ M for HELN-hPR and DHP at 3×10⁻⁹ M for U2OSzfPR. After 16h, medium was removed and replaced with 50 μL/well of medium containing 0.3 mM luciferin. Luminescence signal was monitored in living cells for 2 s per well (BioTek Synergy H4 Hybrid Microplate Reader). Results were expressed as the percentage of the maximum luciferase activity induced by R5020 at 3×10⁻⁸ M for HELN-hPRB cells and DHP at 3×10^{-8} M for U2OS-zfPR cells. Concentration–response curves were obtained with the Hill equation model using the Regtox 7.0.6 Microsoft Excel TM macro (http://www.normalesup.org/~vindimian/fr_index.html), from which effective (EC) and inhibitory concentrations (IC) were derived. For a given chemical, EC₅₀ is defined as the concentration inducing 50% of its maximal effect and IC₅₀ represents the concentration required for 50% inhibition. Relative Effect Potencies (REPs) were calculated by dividing the EC_{50} of the reference compound by that of the tested compound. Chemicals were tested in at least two independent experiments when inactive (i.e. maximal luciferase induction or inhibition below 20%) and three independent experiments when active (i.e. luciferase induction or inhibition above 20 %). Data are expressed as the percentage of the maximum luciferase activity induced by 3×10^{-8} M R5020 or 3×10^{-8} M DHP \pm standard deviation (SD).

3. Results and discussion

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

3.1. hPR and zfPR transactivation by PR, ER and AR reference ligands

P4, R5020, RU486, and DHP were first tested to characterize the response of the established cell lines to reference PR ligands. Some marked differences were revealed in terms of transactivation efficacies and potencies depending of the cell model (Figure 1, Table 2). In HELN-hPR, R5020 was the most efficient ligand with a full agonist response profile and a low EC₅₀ (in the sub-nM range) while it only partially induced luciferase activity in U2OSzfPR. P4 was active in both cell models but was less efficient to induce luciferase activity as compared to R5020 in HELN-hPR and to DHP in U2OS-zfPR. For DHP, a major difference was noticed as it was the most active and efficient steroid in U2OS-zfPR but was unable to induce any luciferase activity in HELN-hPR (Figures 1A, 1B; Table 2). The higher efficacy of DHP to transactivate fish PR as compared to P4 confirms previous in vitro data using transactivation assays for teleost nPR including the zebrafish ², the rainbow fish ¹⁹ and the fathead minnow ²⁰. The species-specificity of DHP to induce zfPR and not hPR likely reflects its crucial role in reproductive endocrinology in most teleost species as maturation-inducing substance (MIS) while in mammals P4 is the endogenous progestagenic hormone. It is however noteworthy that DHP was able to inhibit R5020-induced hPR activity in HELN-hPR cells, but at a quite high concentration (i.e. IC₅₀ 576 nM, Table S1), suggesting that the fish progestin DHP is able to bind to the human nPR but with a much lower affinity than for zfPR. A marked difference was also noticed regarding the efficacy of RU486 to antagonize human and zebrafish PRs (Figure 1C, D). In both cell lines, RU486 behaved as an antagonist ligand but with a 2000-fold higher efficacy in HELN-hPR than in U2OS-zfPR (Table 2), which could reflect a higher binding affinity of RU486 for hPR than zfPR.

Importantly, none of the other steroidal hormones tested, *i.e.* 17β -estradiol, testosterone and 11-ketostestosterone were able to transactivate either hPR or zfPR (Figure S2). In addition, P4, R5020 and DHP were all inactive in HELN cells that express luciferase but no functional receptor (data not shown).

As the cellular context may influence the transcriptional activity of liganded nuclear receptors ²⁴, the reference PR ligands were assessed in U2OS and HeLa cells that were transiently transfected with hPR and zfPR, respectively. The response profiles obtained in transient transfection experiments were very similar to that obtained with U2OS-zfPR and HELN-hPR stable cell lines (Figure S3). These results demonstrate that in our study the cellular context did not influence the biological response and the observed differences between the two cell lines were related to the different PRs.

Altogether, these data highlight that both models respond to reference PR ligands in a sensitive and PR-specific manner, revealing differential transactivation properties depending on the ligands and the origin species of the nPR.

3.2. Synthetic progestins transactivate hPR

The twenty-two pharmaceutical progestins (Table 1) were able to activate luciferase activity in a concentration-dependent manner in HELN-hPR (Figure 2A and 2B) with EC₅₀ values ranging from 0.14 nM for GES to 249 nM for MEP (Table 2). All the tested progestins, except LYN and MEP, were equally or more potent than the endogenous ligand P4, and five of them (*i.e.* MPA, NES, ENG, GES and LNG) had higher relative progestagenic potency than the prototypical synthetic ligand R5020. Interestingly, drospirenone, an analogue of spironolactone, had potent progestagenic activity in HELN-hPR (EC₅₀ 5 nM, Tables 2 and S1, Figure 2B), which was significantly higher than spironolactone and its metabolite canrenone that were previously described as hPR agonists ¹⁰ with EC₅₀ of 1008 nM and 657 nM, respectively (Figure S4).

Further characterization was achieved by coexposing progestins with R5020 1 nM to assess hPR antagonistic activity. The full PR agonists (*i.e.* inducing 80 - 100% of maximum activity, Figure 2A) were unable to inhibit R5020-induced luciferase (data not shown). Conversely, all the progestins that partially induced luciferase activity (Figure 2B) were also able to inhibit R5020-induced luciferase in a concentration-dependent manner to reach the activity level obtained with the compound alone, which is the typical response profile of a partial agonistic ligand (Table 2 and Table S1). For this second category, the calculated IC₅₀ values ranged from 4.70 nM for MGA to 156 nM for EDA.

The progestagenic activities reported herein agree with EC₅₀ values derived from *in vitro* cell-based transactivation assays for 8 pharmaceuticals common to our study using either HELN-hPRB ²² or U2OS-hPR cells ¹⁹ albeit the EC₅₀ reported for tibolone in HG5LN-Gal4-hPR

3.3. Progestins modulated zfPR activty but most of them were antagonists

cells was ten times higher than in our study ²⁵.

The *in vitro* response profiles of progestins were dramatically different when assessing zfPR activity. In contrast to the results obtained on hPR, very few progestins induced zfPR activity (Figure 2C). Only NES and DRO transactivated zfPR, with EC₅₀ values of 1.4 nM and 14.1 nM, respectively (Table 2). In coexposure experiments, both compounds antagonized DHP-induced luciferase activity to reach the level of activity obtained with the compound alone and were therefore considered as partial zfPR agonists (Figure 2D, Tables 2 and S1). Interestingly, the two compounds spironolactone (SPI) and its metabolite canrenone (CAN), were also able to transactivate zfPR to induce luciferase activity in U2OS-zfPR by 10- and 2-fold higher levels than in HELN-hPRB, respectively (Figure S4). Our results thus confirm the study of Ellestad et al., 2014 who demonstrated that DRO activates fathead minnow PR *in vitro* and

newly reports an in vitro progestagenic activity of NES, SPI (the parent compound of DRO), 232 and CAN toward a fish PR. 233 234 None of the other pharmaceutical progestins were able to induce luciferase activity in U2OSzfPR at the concentrations tested (Table S1). Very few studies investigated the interaction of 235 progestins towards fish PR and the number of investigated progestins was limited to few of 236 them. Notwithstanding, the lack of progestagenic activity of progestins toward zfPR reported 237 herein agrees with available in vitro fish PR transactivation assays for the rainbowfish ¹⁹ and 238 the fathead minnow ²⁰. Therefore, our study confirms the lack of progestagenic activity of 239 some progestins and extends this knowledge to a broad range of pharmaceutical progestins in 240 another teleost fish species, the zebrafish. Hence, it suggests that the lack of progestagenic 241 activity of progestins is a common feature in teleost. 242 243 A major finding of our study was to demonstrate that all the progestins were able to fully antagonize DHP-induced luciferase activity in a concentration-dependent manner in the zfPR 244 assay. The IC₅₀ ranged from 14 nM for LNG to 1002 nM for DSG. Remarkably, RU486, a 245 potent antagonist compound on hPR (Figure 1C, Table 2), had a much weaker anti-246 progestagenic activity in U2OS-zfPR, i.e. by 2000-fold, and was the least active anti-247 progestagenic compound in U2OS-zfPR. 248 To ensure that the human cellular context did not influence the biological response measured 249 250 on zfPR in U2OS, we tested the interaction of selected ligands with the full length zfPR in a fish hepatic cell context, the zebrafish liver cell line (ZFL). The ZFL cell line has been shown 251 to be metabolically competent possessing both phase I and phase II enzymes 26,27 and is a 252 253 relevant in vitro zebrafish model to study the interactions of EDCs with NR-regulated signaling pathways such as AhR ²⁷ or ERs ^{28–30}. In ZFL-zfPR cells, the reference agonists 254 DHP, R5020 and P4 were all active, with similar patterns in terms of both effective 255 concentrations and response intensity as compared to the U2OS-zfPR cells (Figure S5-A),

256

which validates the relevance of the established zebrafish cell model. RU486 had no agonistic activity but inhibited DHP-induced luciferase activity at high concentration, which reflects its weak anti-progestagenic activity observed in U2OS-zfPR (Figure S5-B). Most importantly, the ZFL-zfPR assay confirmed the lack of progestagenic activity of MPA and ENG while they antagonized DHP-induced luciferase (Figures S5-C, S5-D). It should be pointed out that the anti-progestagenic activities of MPA and ENG are less pronounced in the ZFL context compared to U2OS-zfPR. These differences might be attributed to the higher metabolic activity of the hepatic cell line compared to U2OS cells, which is important to consider given that progestins are known to be metabolized into actives metabolites possessing diverse endocrine properties ^{17,31}. Based on these data, it can be concluded that the *in vitro* anti-progestagenic activity of progestins was not specific to the cellular context, but on the contrary reflected the intrinsic properties of progestins on zfPR.

Altogether, the *in vitro* comparative data demonstrate that a great majority of the tested synthetic steroidal progestins have potent progestagenic activity towards hPR but anti-progestagenic activity towards zfPR (except DRO and NES).

3.4. Species-specificity of the nuclear progesterone receptor transactivation by progestins

We highlighted major differences regarding the progestagenic activity of progestins towards human and zebrafish PR. Previous studies investigating cross-species differences between mammalian and fish models for several nuclear receptors provided evidence that there exist differential binding affinity, transactivation properties and/or selectivity of ligands and environmental xenobiotics depending on the nuclear receptor studied and the origin species of NR ^{28,32,33}. Among them, the pregnane X receptor (PXR) showed the most significant differences in ligand specificity across species ^{34,35}. Our study further documents new evidence on such interspecies differences between human and fish for the PR. Comparative

analysis of the DBD/LBD amino acid sequences of human NRs and the corresponding orthologs in fish could provide relevant insights into differential transactivation patterns between human and fish ³⁵. For the PR, a single prg gene is transcribed in human into two isoforms, PRA and PRB, by alternate initiation of transcription of two distinct promoters ³⁶ while in zebrafish, one prg gene coding for one PR have been cloned and characterized ². As for other NRs, the DBD region of the PR is very well conserved between human and fish with 90% of sequence similarities while the LBD displayed more variation with only 67% of similarities between amino acid sequences in human and zebrafish ^{2,35,37}. Similar differences in amino acid sequences in the LBD domain between human and fish have been reported for other NRs such as ERs and PPARs for which differences in transactivation properties by environmental contaminants is documented ³⁸. However, none of these latter studies reported such an ambivalent biological activity for a given substance, i.e. which behave as an agonist in human and as an antagonist in fish as in our study for the progestins. In order to explore the differential activity of PR ligands between h and zfPR, a structural analysis and molecular modeling was done (Figure 3, Figure S6). It revealed several amino acid differences within the ligand-binding pockets (LBPs) of zfPR and hPR that are likely to account for their ligand-binding specificities. Using the modeling and docking server EDMon (http://edmon.cbs.cnrs.fr/) ³⁹, we generated homology models of the PR ligand-binding domains (LBDs) of the two species in complex with RU486 or DHP, two ligands displaying distinct species preferences (Table S1, Figure 1). A visual inspection of the h- and zf-models reveals essentially five residue substitutions of amino acids in contact or in proximity to the ligands (G722/C406, V760/L444, S793/P477, F794/I478, L887/V571). Interestingly, the V760/L444 and L887/V571 compensatory mutations allow the preservation of the stabilizing interaction between helix H5 and helix H11 (black doted lines in Figure 3). In the human receptor, V760 (H5) and L887 (H11) make moderate van der Waals interactions with both

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

ligands. In contrast, our model of the zfPR suggests tighter contacts of L444 (H5) and V571 (H11) with the ligands (magenta doted lines in Figure 3) which may account, at least in part, for the higher affinity of DHP for zfPR. Another key substitution is the replacement of the glycine residue G722 in the human receptor by cysteine C406 in zfPR. The additional carbon (Cβ) and sulfur atoms are very likely to provide additional contact points with DHP, thereby participating to increasing further the affinity of this ligand for the zfPR relative to its human homolog (green doted lines in Figure 3D). In contrast, the side chain of C406 generates a strong steric clash with the antagonist extension of RU486 (red asterisk in Figure 3B). Because the position of the bulky RU486 is very much constrained by the amino acid environment, it is very unlikely that the LBP can accommodate the cysteine side-chain without a drastic loss in the binding affinity of RU486.

Overall, the comparison of the LBP and LBD sequences and modeling inform on the differential affinity of investigated ligands between h and zfPR but is not informative enough to explain the observed differences in term of activity. This should be further investigated, for instance by using in depth analysis of the crystal structure of the purified human and zebrafish PR.

3.5. (Eco)toxicological relevance of these findings

The observed differences between the *in vitro* progestagenic activities of the tested substances on human and zebrafish PR raise the question of the relevance of the toxicological information provided using mammalian models to predict possible hazard in other species such as zebrafish. Based on our study, it seems that extrapolation of data from mammalian pharmacology and toxicology to fish species may not be helpful. This point is particularly important in the context of environmental hazard assessment of endocrine disrupting substances. In this respect, our results argue for the development of species-specific strategies

to reliably inform on the endocrine mechanism, properties of environmental chemicals to fish, such approaches being currently lacking from a regulatory point of view.

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

Progestins are now well-recognized as environmental contaminants occurring at low but active concentrations, hence posing a risk to aquatic species such as fish 11. The antiprogestagenic activity reported for most of the investigated progestins as well as the progestagenic activity for NES, DRO and the two spironolactone steroids, SPI and CAN on zfPR, may have consequences on multiple physiological functions mediated by the PR signaling pathway in exposed fish. An increasing number of studies reports multiple effects of progestins in fish notably on reproductive functions with decreases in egg productions and/or cessation of egg laying ¹⁴. Although these in vivo effects are often interpreted with regard to the other endocrine properties of progestins, notably their interaction with the androgen receptor, the in vitro anti-progestagenic activities reported herein may also contribute to the observed effects. Indeed, the inhibition of the DHP-induced zfPR signaling agrees with recent data in homozygous knockout zebrafish for PR females that are infertile due to ovulation defects (anovulation), a physiological response directly attributed to the role of PR in ovulation process ^{4,5}. Remarkably, the inability of females to ovulate, resulting in abdominal swelling, has been observed in a wild population of gudgeon exposed to a pharmaceutical manufacture effluent releasing synthetic steroids, including high concentrations of synthetic progestins ⁴⁰. While the anti-progestagenic activity could provide a new molecular basis to explain the inhibition of eggs released in exposed-female fish to progestins, direct extrapolation of in vitro data to the in vivo situation should however consider pharmacodynamics of progestins that are currently lacking for fish. Whatever, our data stress the need for a better characterization of environmental contaminants towards fish NRs in general, particularly fish PR and to further investigate the effects of progestins on key PRdependent physiological processes.

3	5	6
3	5	7

Acknowledgements

This research was supported by the ANR PROOFS "Occurrences and effects of environmental ligands of progesterone receptor on fish reproduction and neurodevelopment" (ANR-13-CESA-0006-03). Clémentine Garoche was supported by a doctoral fellowship from the ANR PROOFS and the French Ministry of Ecology (grant P190 "Axe de Recherche Ecotoxicologie" to INERIS).

365 References

- 366 (1) Nagahama, Y. 17 Alpha, 20 Beta-Dihydroxy-4-Pregnen-3-One, a Maturation-Inducing
- Hormone in Fish Oocytes: Mechanisms of Synthesis and Action. *Steroids* **1997**, *62* (1),
- 368 190–196.
- 369 (2) Chen, S. X.; Bogerd, J.; García-López, A.; de Jonge, H.; de Waal, P. P.; Hong, W. S.;
- 370 Schulz, R. W. Molecular Cloning and Functional Characterization of a Zebrafish
- Nuclear Progesterone Receptor. *Biol. Reprod.* **2010**, 82 (1), 171–181.
- 372 https://doi.org/10.1095/biolreprod.109.077644.
- 373 (3) Schneider, J. S.; Burgess, C.; Sleiter, N. C.; DonCarlos, L. L.; Lydon, J. P.; O'Malley,
- B.; Levine, J. E. Enhanced Sexual Behaviors and Androgen Receptor
- 375 Immunoreactivity in the Male Progesterone Receptor Knockout Mouse. *Endocrinology*
- **2005**, *146* (10), 4340–4348. https://doi.org/10.1210/en.2005-0490.
- 377 (4) Tang, H.; Liu, Y.; Li, J.; Yin, Y.; Li, G.; Chen, Y.; Li, S.; Zhang, Y.; Lin, H.; Liu, X.;
- et al. Gene Knockout of Nuclear Progesterone Receptor Provides Insights into the
- Regulation of Ovulation by LH Signaling in Zebrafish. Sci. Rep. 2016, 6, 28545.
- 380 https://doi.org/10.1038/srep28545.
- 381 (5) Zhu, Y.; Liu, D.; Shaner, Z. C.; Chen, S.; Hong, W.; Stellwag, E. J. Nuclear Progestin
- Receptor (Pgr) Knockouts in Zebrafish Demonstrate Role for Pgr in Ovulation but Not
- in Rapid Non-Genomic Steroid Mediated Meiosis Resumption. *Front. Endocrinol.*
- 384 (*Lausanne*). **2015**, 6 (MAR), 1–10. https://doi.org/10.3389/fendo.2015.00037.
- 385 (6) Africander, D.; Verhoog, N.; Hapgood, J. P. Molecular Mechanisms of Steroid
- Receptor-Mediated Actions by Synthetic Progestins Used in HRT and Contraception.
- 387 *Steroids* **2011**, 76 (7), 636–652. https://doi.org/10.1016/j.steroids.2011.03.001.
- 388 (7) Besse, J. P.; Garric, J. Progestagens for Human Use, Exposure and Hazard Assessment
- for the Aquatic Environment. *Environ. Pollut.* **2009**, *157* (12), 3485–3494.
- 390 https://doi.org/10.1016/j.envpol.2009.06.012.
- 391 (8) Sitruk-Ware, R. Pharmacological Profile of Progestins. *Maturitas* **2004**, 47 (4), 277–
- 392 283. https://doi.org/10.1016/j.maturitas.2004.01.001.
- 393 (9) Besse, J. P.; Garric, J. Human Pharmaceuticals in Surface Waters. Implementation of a
- Prioritization Methodology and Application to the French Situation. *Toxicol. Lett.*
- **2008**, *176* (2), 104–123. https://doi.org/10.1016/j.toxlet.2007.10.012.

- 396 (10) Creusot, N.; Aït-Aïssa, S.; Tapie, N.; Pardon, P.; Brion, F.; Sanchez, W.; Thybaud, E.;
- Porcher, J.-M.; Budzinski, H. Identification of Synthetic Steroids in River Water
- 398 Downstream from Pharmaceutical Manufacture Discharges Based on a Bioanalytical
- 399 Approach and Passive Sampling. *Environ. Sci. Technol.* **2014**, *48* (7), 3649–3657.
- 400 (11) Fent, K. Progestins as Endocrine Disrupters in Aquatic Ecosystems: Concentrations,
- 401 Effects and Risk Assessment. *Environ. Int.* **2015**, *84*, 115–130.
- 402 https://doi.org/10.1016/j.envint.2015.06.012.
- 403 (12) Kumar, V.; Johnson, A. C.; Trubiroha, A.; Tumová, J.; Grabic, R.; Kloas, W.; Tanaka,
- H.; Kroupová, H. K. Ecotoxicological Research: A Critical Review The Challenge
- 405 Presented by Progestins in Ecotoxicological Research : A Critical Review. **2015**.
- 406 (13) Svensson, J.; Fick, J.; Brandt, I.; Brunström, B. Environmental Concentrations of an
- 407 Androgenic Progestin Disrupts the Seasonal Breeding Cycle in Male Three-Spined
- Stickleback (Gasterosteus Aculeatus). *Aquat. Toxicol.* **2014**, *147*, 84–91.
- 409 https://doi.org/10.1016/j.aquatox.2013.12.013.
- 410 (14) Paulos, P.; Runnalls, T. J.; Nallani, G.; La Point, T.; Scott, A. P.; Sumpter, J. P.;
- Huggett, D. B. Reproductive Responses in Fathead Minnow and Japanese Medaka
- 412 Following Exposure to a Synthetic Progestin, Norethindrone. *Aquat. Toxicol.* **2010**, 99
- 413 (2), 256–262. https://doi.org/10.1016/j.aquatox.2010.05.001.
- 414 (15) Svensson, J.; Fick, J.; Brandt, I.; Brunström, B. The Synthetic Progestin Levonorgestrel
- Is a Potent Androgen in the Three-Spined Stickleback (Gasterosteus Aculeatus).
- 416 Environ. Sci. Technol. **2013**, 47 (4), 2043–2051.
- 417 (16) Brion, F.; Le Page, Y.; Piccini, B.; Cardoso, O.; Tong, S. K.; Chung, B. C.; Kah, O.
- 418 Screening Estrogenic Activities of Chemicals or Mixtures in Vivo Using Transgenic
- 419 (Cyp19a1b-GFP) Zebrafish Embryos. *PLoS One* **2012**, *7* (5), e36069.
- 420 https://doi.org/10.1371/journal.pone.0036069.
- 421 (17) Cano-Nicolau, J.; Garoche, C.; Hinfray, N.; Pellegrini, E.; Boujrad, N.; Pakdel, F.;
- Kah, O.; Brion, F. Several Synthetic Progestins Disrupt the Glial Cell Specific-Brain
- 423 Aromatase Expression in Developing Zebra Fish. *Toxicol. Appl. Pharmacol.* **2016**, *305*.
- 424 https://doi.org/10.1016/j.taap.2016.05.019.
- 425 (18) Hinfray, N.; Tebby, C.; Garoche, C.; Piccini, B.; Bourgine, G.; Ait-Aissa, S.; Kah, O.;
- Pakdel, F.; Brion, F. Additive Effects of Levonorgestrel and Ethinylestradiol on Brain

- 427 Aromatase (Cyp19a1b) in Zebrafish Specific in Vitro and in Vivo Bioassays. *Toxicol*.
- 428 Appl. Pharmacol. **2016**, 307, 108–114. https://doi.org/10.1016/j.taap.2016.07.023.
- 429 (19) Bain, P. a.; Kumar, A.; Ogino, Y.; Iguchi, T. Nortestosterone-Derived Synthetic
- 430 Progestogens Do Not Activate the Progestogen Receptor of Murray–Darling
- Rainbowfish (*Melanotaenia Fluviatilis*) but Are Potent Agonists of Androgen
- 432 Receptors Alpha and Beta. *Aquat. Toxicol.* **2015**, *163*, 97–101.
- 433 https://doi.org/10.1016/j.aquatox.2015.03.021.
- 434 (20) Ellestad, L. E.; Cardon, M.; Chambers, I. G.; Farmer, J. L.; Hartig, P.; Stevens, K.;
- Villeneuve, D. L.; Wilson, V.; Orlando, E. F. Environmental Gestagens Activate
- Fathead Minnow (Pimephales Promelas) Nuclear Progesterone and Androgen
- 437 Receptors in Vitro. *Environ. Sci. Technol.* **2014**, *48*, 8179–8187.
- 438 https://doi.org/10.1021/es501428u.
- 439 (21) Zhao, Y.; Castiglioni, S.; Fent, K. Synthetic Progestins Medroxyprogesterone Acetate
- and Dydrogesterone and Their Binary Mixtures Adversely Affect Reproduction and
- Lead to Histological and Transcriptional Alterations in Zebrafish (Danio Rerio).
- *Environ. Sci. Technol.* **2015**, 150317142110007. https://doi.org/10.1021/es505575v.
- 443 (22) Bellet, V.; Hernandez-Raquet, G.; Dagnino, S.; Seree, L.; Pardon, P.; Bancon-Montiny,
- 444 C.; Fenet, H.; Creusot, N.; Ait-Aissa, S.; Cavailles, V.; et al. Occurrence of Androgens
- in Sewage Treatment Plants Influents Is Associated with Antagonist Activities on
- Other Steroid Receptors. Water Res. **2012**, 46 (6), 1912–1922.
- 447 https://doi.org/10.1016/j.watres.2012.01.013.
- 448 (23) Balaguer, P.; François, F.; Comunale, F.; Fenet, H.; Boussioux, A. M.; Pons, M.;
- Nicolas, J. C.; Casellas, C. Reporter Cell Lines to Study the Estrogenic Effects of
- 450 Xenoestrogens. *Sci. Total Environ.* **1999**, *233* (1–3), 47–56.
- 451 (24) Kerdivel, G.; Habauzit, D.; Pakdel, F. Assessment and Molecular Actions of
- Endocrine-Disrupting Chemicals That Interfere with Estrogen Receptor Pathways. *Int.*
- 453 *J. Endocrinol.* **2013**, 2013, 501851. https://doi.org/10.1155/2013/501851.
- 454 (25) Escande, A.; Servant, N.; Rabenoelina, F.; Auzou, G.; Kloosterboer, H.; Cavailles, V.;
- Balaguer, P.; Maudelonde, T. Regulation of Activities of Steroid Hormone Receptors
- by Tibolone and Its Primary Metabolites. J. Steroid Biochem. Mol. Biol. 2009, 116 (1–
- 457 2), 8–14. https://doi.org/10.1016/j.jsbmb.2009.03.008.

- 458 (26) Le Fol, V.; Aït-Aïssa, S.; Cabaton, N.; Dolo, L.; Grimaldi, M.; Balaguer, P.; Perdu, E.;
- Debrauwer, L.; Brion, F.; Zalko, D. Cell-Specific Biotransformation of Benzophenone-
- 2 and Bisphenol-S in Zebrafish and Human in Vitro Models Used for Toxicity and
- 461 Estrogenicity Screening. *Environ. Sci. Technol.* **2015**, 49 (6), 3860–3868.
- https://doi.org/10.1021/es505302c.
- 463 (27) Eide, M.; Rusten, M.; Male, R.; Jensen, K. H. M.; Goksøyr, A. A Characterization of
- the ZFL Cell Line and Primary Hepatocytes as in Vitro Liver Cell Models for the
- 465 Zebrafish (Danio Rerio). *Aquat. Toxicol.* **2014**, *147*, 7–17.
- 466 https://doi.org/10.1016/j.aquatox.2013.11.023.
- 467 (28) Cosnefroy, A.; Brion, F.; Maillot-Maréchal, E.; Porcher, J.-M.; Pakdel, F.; Balaguer,
- 468 P.; Aït-Aïssa, S. Selective Activation of Zebrafish Estrogen Receptor Subtypes by
- Chemicals by Using Stable Reporter Gene Assay Developed in a Zebrafish Liver Cell
- 470 Line. *Toxicol. Sci.* **2012**, *125* (2), 439–449. https://doi.org/10.1093/toxsci/kfr297.
- 471 (29) Le Fol, V.; Aït-Aïssa, S.; Sonavane, M.; Porcher, J.-M.; Balaguer, P.; Cravedi, J.-P.;
- Zalko, D.; Brion, F. In Vitro and in Vivo Estrogenic Activity of BPA, BPF and BPS in
- Zebrafish-Specific Assays. *Ecotoxicol. Environ. Saf.* **2017**, *142*, 150–156.
- https://doi.org/10.1016/j.ecoenv.2017.04.009.
- 475 (30) Serra, H.; Scholze, M.; Altenburger, R.; Busch, W.; Budzinski, H.; Brion, F.; Aït-
- 476 Aïssa, S. Combined Effects of Environmental Xeno-Estrogens within Multi-
- 477 Component Mixtures: Comparison of in Vitro Human- and Zebrafish-Based
- Estrogenicity Bioassays. *Chemosphere* **2019**, 227, 334–344.
- 479 https://doi.org/10.1016/j.chemosphere.2019.04.060.
- 480 (31) Enríquez, J.; Lemus, A. E.; Chimal-Monroy, J.; Arzate, H.; García, G. A.; Herrero, B.;
- Larrea, F.; Pérez-Palacios, G. The Effects of Synthetic 19-Noprogestins on
- Osteoblastic Cell Function Are Mediated by Their Non-Phenolic Reduced Metabolites.
- 483 *J. Endocrinol.* **2007**, *193* (3), 493–504. https://doi.org/10.1677/JOE-06-0038.
- 484 (32) Molina-Molina, J. M.; Escande, A.; Pillon, A.; Gomez, E.; Pakdel, F.; Cavaillès, V.;
- Olea, N.; Aït-Aïssa, S.; Balaguer, P. Profiling of Benzophenone Derivatives Using Fish
- and Human Estrogen Receptor-Specific in Vitro Bioassays. *Toxicol. Appl. Pharmacol.*
- **2008**, 232 (3), 384–395. https://doi.org/10.1016/j.taap.2008.07.017.
- 488 (33) Hotchkiss, A. K.; Rider, C. V; Blystone, C. R.; Wilson, V. S.; Hartig, P. C.; Ankley, G.
- T.; Foster, P. M.; Gray, C. L.; Gray, L. E. Fifteen Years after "Wingspread"--

- Environmental Endocrine Disrupters and Human and Wildlife Health: Where We Are
- 491 Today and Where We Need to Go. *Toxicol. Sci.* **2008**, *105* (2), 235–259.
- 492 https://doi.org/10.1093/toxsci/kfn030.
- 493 (34) Ekins, S.; Reschly, E. J.; Hagey, L. R.; Krasowski, M. D. Evolution of Pharmacologic
- Specificity in the Pregnane X Receptor. *BMC Evol. Biol.* **2008**, 8 (1), 103.
- 495 https://doi.org/10.1186/1471-2148-8-103.
- 496 (35) Zhao, Y.; Zhang, K.; Giesy, J. P.; Hu, J. Families of Nuclear Receptors in Vertebrate
- 497 Models: Characteristic and Comparative Toxicological Perspective. *Sci. Rep.* **2015**, *5*,
- 498 8554. https://doi.org/10.1038/srep08554.
- 499 (36) Giangrande, P.; McDonnell, D. The A and B Isoforms of the Human Progesterone
- Receptor: Two Functionally Different Transcription Factors Encoded by a Single Gene.
- 501 Recent Prog. Horm. Res. **1999**, 54, 291–314.
- 502 (37) Hanna, R. N.; Daly, S. C. J.; Pang, Y.; Anglade, I.; Kah, O.; Thomas, P.; Zhu, Y.
- 503 Characterization and Expression of the Nuclear Progestin Receptor in Zebrafish
- Gonads and Brain. *Biol. Reprod.* **2010**, 82 (1), 112–122.
- 505 https://doi.org/10.1095/biolreprod.109.078527.
- 506 (38) Grimaldi, M.; Boulahtouf, A.; Delfosse, V. Reporter Cell Lines to Evaluate the
- 507 Selectivity of Chemicals for Human and Zebrafish Estrogen and Peroxysome
- Proliferator Activated γ Receptors. **2015**, 9 (June), 1–9.
- 509 https://doi.org/10.3389/fnins.2015.00212.
- 510 (39) Schneider, M.; Pons, J.-L.; Bourguet, W.; Labesse, G. Towards Accurate High-
- Throughput Ligand Affinity Prediction by Exploiting Structural Ensembles, Docking
- Metrics and Ligand Similarity. *Bioinformatics* **2020**, *36* (1), 160–168.
- 513 https://doi.org/10.1093/bioinformatics/btz538.

518

- 514 (40) Sanchez, W.; Sremski, W.; Piccini, B.; Palluel, O.; Maillot-Maréchal, E.; Betoulle, S.;
- Jaffal, A.; Aït-Aïssa, S.; Brion, F.; Thybaud, E.; et al. Adverse Effects in Wild Fish
- Living Downstream from Pharmaceutical Manufacture Discharges. *Environ. Int.* **2011**,
- 517 37 (8), 1342–1348. https://doi.org/10.1016/j.envint.2011.06.002.

Table 1: Classification of natural hormones and natural and synthetic nPR ligands tested on HELN-hPRB and U2OS-zfPR cells.

Classification		Compound	Abbre viation	Uses	Molecular weight (g/mol)	CAS	Structure
Natural progestin in human and fish		Progesterone	P4 Clinical use		314.46	57-83-0	
Natural progestin in fish		$17~\alpha$,20 β -dihydroxy-4-pregnen-3-one	DHP		332.48	332.48 1662-06-2	
Synthetic progestin derived from 19- norprogesterone		Promegestone	R5020 Clinical use		326.47	34184-77-5	
PR antagonist		Mifepristone	RU486 Clinical use		429.60	84371-65-3	
Synthetic progestin retroprogesterone, isomer of P4		Dydrogesterone	DYD	Clinical use	312.45	152-62-5	
	Derived from 17α- hydroxyprogesterone	Medroxyprogesterone	MEP	Clinical use	344.49	520-85-4	
Progestins structurally related to progesterone		Medroxyprogesterone acetate	MPA	Clinical use	386.52	71-58-9	
		Megestrol acetate	MGA	Clinical use	384.51	595-33-5	
		Chlormadinone acetate	CMA	Clinical use	406.94	302-22-7	app.
		Cyproterone acetate	CPA	Clinical use	416.94	427-51-0	× S
Progestins structur	Derived from 19-norprogesterone	Promegestone	R5020	Clinical use	326.47	34184-77-5	
		Nestorone	NES	Clinical use	370.48	7759-35-5	
		Nomegestrol acetate	NGA	Clinical use	370.48	58652-20-3	age of
	Derived from 17α-hydroxy-19- norprogesterone	Gestonorone	GRN	Clinical use of gestonorone caproate	316.43	2137-18-0	.adt

related to testosterone: derived from 19- nortestosterone	Estranes	Ethisterone	ETH	Stopped	312.45	434-03-7	
		Ethynodiol diacetate	EDA	Clinical use	384.51	297-76-7	reber
		Lynestrenol	LYN	Clinical use	284.44	52-76-6	
		Norethindrone acetate	NEA	Clinical use	340.46	51-98-9	retain
		Norethindrone	NET	Clinical use	298.42	68-22-4	
		Tibolone	TIB	Clinical use	312.4	5630-53-5	
Progestins structurally related to testost nortestosterone	Gonanes	Desogestrel	DSG	Clinical use	310.47	54024-22-5	
		Etonogestrel	ENG	Clinical use, metabolite of desogestrel	324.45	54048-10-1	
		Gestodene	GES	Clinical use	310.43	60282-87-3	
		Levonorgestrel	LNG	Clinical use	312.45	797-63-7	
		Norgestimate	NTE	Clinical use	369.50	35189-28-7	adr.
		Norgestrel	NGL	Clinical use	312.45	6533-00-2	
Progestin structurally related to spironolactone		Drospirenone	DRO	Clinical use	366.49	67392-87-4	Sh
Natural hormones and precursors		Pregnenolone (progesterone precursor)	P5	Clinical use	316.48	145-13-1	
		17β-estradiol	E2	Clinical use	272.38	50-28-2	
		Testosterone	T	Clinical use	288,42	58-22-0	de

Table 2: Calculated EC₅₀ and IC₅₀ (nM) in HELN-hPRB and U2OS-zfPR cells.

		HELN-PRB				U2OS-zfPR				
		Agonism			Antagonism	Agonism			Antagonism	
Classification	Abb	$EC_{50} \pm sd (nM)$	max ± sd (%)	REP	$IC_{50} \pm sd (nM)$	$EC_{50} \pm sd (nM)$	max ± sd (%)	REP	IC ₅₀ ± sd (nM)	
Reference compounds	P4	13.5 ± 7.14	70 ± 9	0.02	17.1 ± 15.7	1.97 ± 0.57	40 ± 7	0.95	2.09 ± 0.33	
	R5020	0.33 ± 0.10	100	1	-	1.93 ± 0.60	64 ± 11	0.97	-	
	DHP	ne			576 ± 319	1.87 ± 0.44	100	1	-	
	RU486	ne			1.04 ± 0.28	ne			2253 ± 292	
	DYD	8.03 ± 3.28	66 ± 13	0.04	14.5	ne			24.9 ± 6.38	
	MEP	249 ± 105	37 ± 8	0.001	39.6 ± 23.4	ne			91.4 ± 55.9	
	MPA	0.20 ± 0.05	68 ± 15	1.7	8.08 ± 5.74	ne			30.0 ± 7.86	
	MGA	0.57 ± 0.04	74 ± 14	0.58	4.70 ± 3.87	ne			95.2 ± 55.5	
	CMA	0.65 ± 0.07	84 ± 7	0.50	ne	ne			125 ± 22	
	CPA	1.15 ± 0.16	79 ± 0	0.29	ne	ne			244 ± 93.3	
	NES	0.25 ± 0.03	90 ± 5	1.34	ne	1.41 ± 0.41	40 ± 2	1.33	6.39 ± 4.00	
	NGA	0.60 ± 0.22	92 ± 14	0.55	ne	ne			17.8 ± 6.99	
	GRN	18.4 ± 5.11	50 ± 15	0.02	34.9 ± 15.0	ne			26.2 ± 11.3	
	ETH	6.20 ± 0.61	55 ± 12	0.05	14.1 ± 4.42	ne			69.5 ± 8.17	
Other	EDA	15.3 ± 4.80	62 ± 19	0.02	156 ± 117	ne			354 ± 295	
progestins	LYN	25.7 ± 10.8	56 ± 2	0.01	61.9 ± 13.2	ne			503 ± 110	
	NEA	0.85 ± 0.57	90 ± 12	0.39	ne	ne			22.2 ± 0.55	
	NET	0.93 ± 0.27	83 ± 4	0.35	ne	ne			34.3 ± 1.66	
	TIB	9.97 ± 1.33	85 ± 6	0.03	ne	ne			146	
	DSG	14.1 ± 6.80	72 ± 24	0.02	76.0 ± 51.2	ne			1002	
	ENG	0.18 ± 0.04	94 ± 7	1.77	ne	ne			148 ± 98	
	GES	0.14 ± 0.05	95 ± 5	2.43	ne	ne			15.2 ± 16.2	
	LNG	0.16 ± 0.04	96 ± 6	2.08	ne	ne			14.0 ± 7.41	
	NTE	1.11 ± 0.26	78 ± 10	0.30	ne	ne			77.4 ± 4.16	
	NGL	0.47 ± 0.12	101 ± 1	0.70	ne	ne			43.6 ± 17.2	
	DRO	5.72 ± 1.38	60 ± 14	0.06	58.0 ± 66.1	14.1 ± 4.49	30±6	0.13	16.1 ± 1.44	

REP: Relative potency in HELN-hPRB cells ($EC_{50}(R5020)/EC_{50}(chemical)$) and U2OS-zfPR cells ($EC_{50}(DHP)/EC_{50}(chemical)$). Standard deviations (sd); ne: no effect.




Figure 1: Dose-response curves of the activity of reference ligands in HELN-hPRB and U2OS-zfPR cells expressed as the percentage of the maximum luciferase activity induced by $3x10^{-8}$ M R5020 (A,C) or $3x10^{-8}$ M DHP (B,D). P4: progesterone; DHP: 17α ,20 β -dihydroxy-4-pregnen-3-one; R5020: promegestone, RU486: mifepristone. Error bars represent standard deviation.




Figure 2: Dose-response curves of the activity of progestins in HELN-hPRB and U2OS-zfPR cells expressed as the percentage of the maximum luciferase activity induced by 3x10⁻⁸ M R5020 (A, B) or 3x10⁻⁸ M DHP (C, D). P4: progesterone; DHP: 17α,20β-dihydroxy-4-pregnen-3-one; R5020: promegestone, P5: pregnenolone; DYD: dydrogesterone; MEP: medroxyprogesterone; MPA: medroxyprogesterone acetate; MGA: megestrol acetate; CMA: chlormadinone acetate; CPA: cyproterone acetate; NES: nestorone; NGA: nomegestrol acetate; ETH: ethisterone; EDA: ethynodiol diacetate; LYN: lynestrenol; NEA: norethindrone acetate; NET: norethindrone; TIB: tibolone; DSG: desogestrel; ENG: etonogestrel; GES: gestodene; LNG: levonorgestrel; NTE: norgestimate; NGL: norgestrel; DRO: drospirenone; GRN: gestonorone. Error bars represent standard deviation (SD, n=3 replicates per concentration). All curves for individual compounds are presented separately in Supplementary Materials, Table S1.




Figure 3: Structural analysis of species-specificity for RU486 and DHP. Structure (A), PDB code 2w8y, and docking model (B) of RU486 bound to human and zebrafish PR, respectively. (C, D) Docking models of DHP bound to human and zebrafish PR, respectively. The ligands and residues discussed in the main text are shown as sticks. The structural elements of PR LBD are shown in grey and labelled. The dashed lines denote the interactions described in the text. The red asterisk denotes a steric clash between C406 and RU486. Docking models were generated using the server EDMon (http://edmon.cbs.cnrs.fr) and the default parametters. Figures were prepared with PyMOL (http://pymol.org/).

Supporting information

Human and zebrafish nuclear progesterone receptors are differently activated by progestins

Clémentine Garoche, Selim Aït-Aïssa, Abdelhay Boulahtouf, Nicolas Creusot, William Bourget, Patrick Balaguer, François Brion

Table of content

Figure S1: Constructions of the cell lines HELN-hPRB (A) and U2OS-zfPR (B).

Table S1: Typical concentration-response curves of the activity of progestins in HELN-hPRB and U2OS-zfPR cells.

Figure S2: HELN-hPRB cells (A) and U2OS-zfPR (B) cells were treated with indicated concentrations of 17β-estradiol (E2), testosterone (T) and 11-Ketotestosterone (11-KT).


Figure S3: Concentration-response curves of the activity of progestins in U2OS cells expressing hPR (A) and HeLa cells expressing zfPR (B).

Figure S4: Activity of spironolactone and canrenone towards h and zfPR.

Figure S5: Activity of progestins in ZFL-zfPR cells.

Figure S6: Amino acids sequence alignment of the human (hPR-B) and zebrafish (zfPR) progesterone receptor.

(A) HELN-hPRB



(B) U2OS-zfPR




Figure S1: Constructions of the cell lines HELN-hPRB (A) and U2OS-zfPR (B). Each contains six domains. Domain A/B: activation factor; domain C: human estrogen receptor hERα DNA binding domain (C251-M316); domain D: hinge; domain E: hPR-B (A) or zfPR (B) ligand binding domain.

Table S1: Typical concentration-response curves of the activity of progestins in HELN-hPRB and U2OS-zfPR cells. Results are expressed as percentage of the maximum luciferase activity induced by 3×10^{-8} M R5020 in HELN-hPRB or 3×10^{-8} M DHP in U2OS-zfPR. Cells were treated with progestins alone (black circles) or in co-exposure with R5020 or DHP at concentrations inducing 80% of the maximum luciferase activity (10^{-8} M R5020 and 3×10^{-9} M respectively) (white circles). Error bars represent standard deviation.





Table S1 (continued)






Figure S2: HELN-hPRB cells (A) and U2OS-zfPR (B) cells were treated with indicated concentrations of 17β-estradiol (E2), testosterone (T) and 11-Ketotestosterone (11-KT). Results are expressed as the percentage of the maximum luciferase activity induced by $3x10^{-8}$ M R5020 (A) or $3x10^{-8}$ M DHP (B). Error bars represent standard deviation. The absence of luciferase activity by the steroidal hormones indicates the specificity of response of the cell models.




Figure S3: Concentration-response curves of the activity of progestins in U2OS cells expressing hPR (A) and HeLa cells expressing zfPR (B). The results are expressed as the percentage of the maximum luciferase activity induced by $3x10^{-8}$ M R5020 (A) or $3x10^{-8}$ M DHP: 17α ,20β-dihydroxy-4-pregnen-3-one; DHP (B). P4: progesterone; R5020: MPA: promegestone, medroxyprogesterone acetate; ENG: etonogestrel; RU486: mifepristone. Error bars represent standard deviation. U2OS cells were transiently cotransfected by a plasmid expressing ERE-luciferase and a second one expressing the hPR with the EhRa DNA binding domain. HeLa cells were transiently cotransfected by a plasmid expressing ERE-luciferase and a second one expressing the zfPR with the hERa DNA binding domain.




Figure S4: Activity of spironolactone and canrenone towards h and zfPR. Typical concentration-response curves of the activity of spironolactone and canrenone in HELN-hPRB and U2OS-zfPR cells expressed as percentage of the maximum luciferase activity induced by 3×10^{-8} M R5020 in HELN-hPRB or 3×10^{-8} M DHP in U2OS-zfPR. Cells were treated with chemical substances alone (black circles) or in coexposure with R5020 or DHP at concentrations inducing 80% of the maximum luciferase activity (10^{-8} M R5020 and 3×10^{-9} M respectively) (white circles). Error bars represent standard deviation.




Figure S5: Activity of progestins in ZFL-zfPR cells. Results are expressed as the percentage of the maximum luciferase activity induced by $3x10^{-8}$ M DHP. P4: progesterone; DHP: $17\alpha,20\beta$ -dihydroxy-4-pregnen-3-one; R5020: promegestone, MPA: medroxyprogesterone acetate; ENG: etonogestrel; RU486: mifepristone. Coexposure are made with DHP at a concentration inducing 80% of the maximum luciferase activity (3×10^{-9} M). Error bars represent standard deviation. Letters correspond to significant differences between groups after t-test Student, *** p<0.001.

hPRB (V633-K933) VLGGRKFKKFNKVRVVRALDAVALPOPVGVPNESOALSORFTFSPGODIOLIPPLINLLMS MLGGRKMKRFAGLKVMGLSPSLMFQSPLSLLTDGQTLSSLPCMSAMRELQLSPQMISILEN zfPR (M317-K617) IEPDVIYAGHDNTKPDTSSSLLTSLNQLGERQLLSVVKWSKSLPGFRNLHIDDQITLIQYS IEPOVVYSGYDNTOPEVPHLLLNSLNRLCERÖLLWIVRWSKSLPGFRNLHINDOMTLIÖYS WMSLMVFGLGWRSYKHVSGQMLYFAPDLILNEQRMKESSFYSLCLTMWQIPQEFVKLQVSQ WMGLMLFSLGWRTFONVTPDYLYFAPDLVLSNDOLRRSPIYDLCLAMOFVPOEFANLOVTK EEFLCMKVLLLLNTIPLEGLRSQTQFEEMRSSYIRELIKAIGLRQKGVVSSSQRFYQLTKL _CMKALMLLNTVPLEGLKSQTQFDEMRQNYICELSKAIQLKEKGVVASSQRFYHLTKL LDNLHDLVKQLHLYCLNTFIQSRALSVEFPEMMSEVIAAQLPKILAGMVKPLLFHKK MDNMHEIVKKVNLYCLTTFIOADAMKVEFPEMMTEVIASOLPKVLAGMVKP

Figure S6. Amino acids sequence alignment of the human (hPR-B) and zebrafish (zfPR) progesterone receptor ligand binding domain.

The five residue substitutions of amino acids in contact or in proximity to the ligands (G722/C406, V760/L444, S793/P477, F794/I478, L887/V571) are framed.